Skip to main content

Author: Customer Service

Maui Land & Pineapple Company, Inc. Reports Fiscal Second Quarter 2026 Results

KAPALUA, Hawai‘i, Aug. 14, 2026 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results for the six months ended June 30, 2026. The first half of the year was a period of steady progress for the Company. Its commercial real estate and land leasing businesses continued to generate dependable, recurring revenue totaling approximately $6.6 million for the six months ended June 30, 2026. The Company continued to invest across its business units including its development projects, agricultural ventures, and infrastructure facilities which will continue to build long-term value for the Company. “Our commercial real estate and land leasing businesses continue to provide a stable foundation, and we are reinvesting that stability into a development pipeline we believe will produce meaningful...

Continue reading

XMax Inc. Announces Second Quarter 2026 Financial Results

Company Reports Net Income of $32.4 million and Cash Position of $34.6 Million LOS ANGELES, Aug. 14, 2026 (GLOBE NEWSWIRE) — XMax Inc. (NASDAQ: XMAX, “XMAX” or the Company), a distributor of contemporary furniture and artificial intelligence software and platform-based service provider, today announced financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial HighlightsNet Sales: $2.7 million, up 7% from $2.6 million in the second quarter of 2025 Gross Profit: $1.1 million, representing a 40% gross margin, compared to gross profit of $1.3 million and gross margin of 50% for the second quarter of 2025 Net Income: $32.4 million, driven primarily by a $42.1 million unrealized gain on the Company’s investment in Preamble Capital, compared to a net loss of $(0.3) million in the second quarter...

Continue reading

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study Completed the April 2026 private placement and received shareholder approval of the Series B and Series C tranches, enabling access to up to $50 million in potential additional financing, subject to achievement of program milestones and investor participationNEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results and provided recent business highlights for the quarter ended June 30, 2026, including updates on its lead...

Continue reading

OBOOK Holdings Inc. (NASDAQ: OWLS) Announces Preliminary First Half 2026 Revenue and Highlights Rapid Commercial Scaling of OwlPay Harbor

Preliminary unaudited total revenue for the six months ended June 30, 2026 expected to be approximately US$3.85 million to US$3.90 million OwlPay Harbor, the Company’s digital currency-based platform for cross-border enterprise payments, reached approximately US$96 million in annualized payment volume based on July activity, and approximately US$130 million based on completed payment volume during the trailing 30 days as of August 13, 2026 Harbor has been in commercial scaling for only approximately six months and has recorded six consecutive months of sequential payment volume growth, including July payment volume growth of 107.6% month over month and transaction count growth of 109.5% Complete unaudited first half 2026 financial results will be released after the U.S. market closes on Friday, August 21, 2026ARLINGTON, Va., Aug. 15,...

Continue reading

Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

Quarter highlighted by steadily increasing patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, today reported financial results and operating highlights for the three and six months ended June 30, 2026. Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “The second quarter of 2026 represented a watershed moment in the history of Vivos as we continued to lay the foundation...

Continue reading

reAlpha (Nasdaq: AIRE) Reports Second-Quarter 2026 Financial Results 

DUBLIN, Ohio, Aug. 14, 2026 (GLOBE NEWSWIRE) — reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), an AI-powered real estate technology company, today announced financial results and business highlights for the second quarter ended June 30, 2026. Financial Highlights (All figures are approximate and compared to the second quarter of 2025 unless otherwise stated.)Revenue totaled approximately $1.1 million in the second quarter of 2026, compared to approximately $1.3 million in the second quarter of 2025, a decrease of 11%.Homebuying Services Segment revenue was approximately $0.8 million, compared to approximately $1.0 million in the prior-year period, a decrease of 20%. Revenue from reAlpha Mortgage and Prevu, which was acquired in November 2025, partly offset the absence of approximately $0.6 million of GTG Financial...

Continue reading

Solana Company Reports Second Quarter 2026 Financial Results

PHILADELPHIA, Aug. 14, 2026 (GLOBE NEWSWIRE) — Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to the Solana ecosystem, today announced its results for the quarter ended June 30, 2026. During the second quarter, the Company generated $2.5 million in revenue and achieved strategic milestones, including building out its first institutional validator cluster in Tokyo, expanding its institutional infrastructure across Asia-Pacific, growing its digital asset treasury, staking, and advisory businesses, and completing the divestiture of its legacy medical device business. Second Quarter Operational HighlightsBuilt out the Company’s first institutional validator cluster in Tokyo under the Pacific Backbone initiative. Announced...

Continue reading

Precipio Announces Q2-2026 Financial Results

Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, Conn., Aug. 14, 2026 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces financial results for the second quarter that ended June 30, 2026. Below are some of the key financial performance metrics for the Company. For additional results please see the Company’s Form 10-Q which was filed today.Revenue – $7.0M vs. $6.7M in Q1-2026, and up 22% YoY from $5.7M in Q2-2025. This comprised of $6.1M in pathology revenue (up from $6.0M in Q1) and $0.9M in product revenue (up from $0.66M in Q1). Adjusted EBITDA – $0.4M vs. $(0.2)M in Q1-2026. The change was driven by increased revenues of $0.3 million and a decrease in stock based compensation expense of $0.2M. Cash flow –...

Continue reading

PS International Group Ltd. Receives Nasdaq Non-Compliance Notice for Minimum Market Value of Listed Securities Requirement

HONG KONG, Aug. 14, 2026 (GLOBE NEWSWIRE) — PS International Group Ltd.  (“PSIG” or the “Company”) (Nasdaq: PSIG), a long-established global logistics and supply chain solution provider, today issued this press release to disclose that it received an official deficiency letter dated August 12, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). Per Nasdaq Listing Rule 5550(b)(2), issuers on the Nasdaq Capital Market must maintain a minimum Market Value of Listed Securities (“MVLS”) of US35 million MVLS threshold during the measurement period. The Nasdaq letter further confirmed the Company does not satisfy the two alternative continued listing criteria under Rule 5550(b):Rule 5550(b)(1): Minimum stockholders’ equity of US$2,500,000;Rule 5550(b)(3): Minimum annual net income from continuing...

Continue reading

Cumulus Media Reports Operating Results for the Second Quarter 2026

ATLANTA, GA, Aug. 14, 2026 (GLOBE NEWSWIRE) — Cumulus Media Inc. (OTC: CMLS.Q) (the “Company,” “Cumulus Media,” “we,” “us,” or “our”) today announced operating results for the three and six months ended June 30, 2026. Mary G. Berner, President and Chief Executive Officer of Cumulus Media, said, “We are pleased to report our second quarter earnings. With our plan of reorganization confirmed by the court and the FCC approval process well underway, we are positioned to emerge from Chapter 11 with a stronger balance sheet to capitalize on future market opportunities.” Operating Summary (dollars in thousands, except percentages and per share data): For the three months ended June 30, 2026, the Company reported net revenue of $167.9 million, a decrease of 9.7% from...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.